Back to Journals » Research Reports in Clinical Cardiology » Volume 4
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Advances in coronary stent technology: current expectations and new developments
Received 5 April 2013
Accepted for publication 8 May 2013
Published 1 July 2013 Volume 2013:4 Pages 85—96
DOI https://doi.org/10.2147/RRCC.S34408
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
William M Wilson, Nicholas LM Cruden
Edinburgh Heart Center, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
Abstract: The field of percutaneous coronary intervention has witnessed many advances over the last few decades that have served to make it a safe and effective treatment for patients with angina due to coronary artery disease. Although the development of drug eluting stents has significantly reduced the need for repeat revascularization procedures, in-stent restenosis, stent thrombosis, and an increase in bleeding events related to the prolonged use of dual antiplatelet therapy remain important issues. The quest for the optimal coronary stent continues with numerous recent developments that are designed to further improve clinical outcomes following percutaneous coronary intervention. This review will focus on recent advances in coronary stent technology, including bioabsorbable stents and dedicated bifurcation stents, and discuss developments on the horizon.
Keywords: coronary stent, bioabsorbable stent, bifurcation stent
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution
- Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.